|View printer-friendly version|
Spring Bank to Host a Conference Call to Discuss Inarigivir Data Presented at the International Liver Congress™ (EASL 2019)
The Company will also discuss new data for inarigivir including immune-activation findings from a clinical study involving the administration of inarigivir 400mg to healthy volunteers.
Conference Call Details
A replay of the call may be accessed by visiting Spring Bank’s website.
Source: Spring Bank Pharmaceuticals, Inc.